Vienna - Delayed Quote • EUR Abbott Laboratories (ABT.VI) Follow Compare 108.06 -1.84 (-1.67%) At close: 5:32:06 PM GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Nevro Stock Falls Despite Q4 Sales Beat on Strong SCS Demand NVRO's preliminary fourth-quarter revenues showcase decline in worldwide and U.S. revenues. Jim Cramer on Abbott Laboratories (ABT): ‘Not Understood Very Well Because They’re Doing Tremendous Stuff When It Comes To Diabetes. People Don’t Seem To Care’ We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against the other stocks. In one of his latest appearances on CNBC’s Squawk on the Street, Jim Cramer started the morning by […] Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped PacBio reports dismal preliminary fourth-quarter 2024 results, caused by lower instrument. New launches and clinical focus set the stage for market growth in 2025. QuidelOrtho Stock Down Despite Solid Preliminary Q4 Revenues QDEL's preliminary fourth-quarter revenues align with the company's expectations. Returns At Abbott Laboratories (NYSE:ABT) Are On The Way Up What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst... Abbott (ABT) Outpaces Stock Market Gains: What You Should Know The latest trading day saw Abbott (ABT) settling at $113.19, representing a +0.78% change from its previous close. AngioDynamics Stock Up on Q2 Earnings Beat, Gross Margin Declines ANGO registers overall strong top-line results on a pro-forma basis in second-quarter fiscal 2025, driven by strength in the Med Tech business. Abbott Stock Trades at a Discounted P/B Value: To Buy or Not to Buy? ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology and Consumer Diagnostics. Insiders At Abbott Laboratories Sold US$3.0m In Stock, Alluding To Potential Weakness Over the past year, many Abbott Laboratories ( NYSE:ABT ) insiders sold a significant stake in the company which may... BDSX Stock Rises After Publication of Study Data for Nodify CDT Test Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal. Here's Why You Should Retain BDX Stock in Your Portfolio for Now BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns. Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know In the latest trading session, Abbott (ABT) closed at $113.04, marking a -0.69% move from the previous day. Is Abbott Laboratories (NYSE:ABT) the Best January Dividend Stock to Buy? We recently compiled a list of the 10 Best January Dividend Stocks To Buy. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against the other January dividend stocks. In 2024, dividend stocks fell short of investor expectations, largely due to the continuing AI boom and a heightened interest […] Abbott Laboratories (NYSE:ABT) Could Easily Take On More Debt Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of... Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year? Here is how Abbott (ABT) and Acurx Pharmaceuticals, Inc. (ACXP) have performed compared to their sector so far this year. Abbott Hosts Conference Call for Fourth-Quarter Earnings Abbott (NYSE: ABT) will announce its fourth-quarter 2024 financial results on Wednesday, Jan. 22, before the market opens. 3 Dividend Growth Beasts That Have Raised Their Payouts for a Combined 165 Years Here's a list of stocks that have been raising their dividend payments consistently for more than 50 consecutive years. Combined, they add up to 165 years' worth of increases. Three of the best dividend stocks you can buy and hold today are Target (NYSE: TGT), Hormel Foods (NYSE: HRL), and Abbott Laboratories (NYSE: ABT). Jim Cramer’s Take on Abbott Laboratories (ABT): Bold Predictions for the Future We recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been one of Jim Cramer’s favorite topics lately. The […] Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store. Performance Overview Trailing total returns as of 1/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 Return ABT.VI S&P 500 YTD -1.04% +0.81% 1-Year +6.45% +24.48% 3-Year +3.12% +27.71%